Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial

ConclusionPharmacotherapy of patients with autism spectrum disorder resulted in behavioral improvement within one week and lasted at least 22 weeks. Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial. Our trial supports previous results of drug efficacy and safety in patients with autism spectrum disorder from other trials and extends the evidence ‐based support for choosing an FDA‐approved drug for initial pharmacotherapy for autism spectrum disorder.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 6, 2019 Category: Drugs & Pharmacology Authors: C. Lindsay De Vane, Jane M. Charles, Ruth K. Abramson, John E. Williams, Laura A. Carpenter, Sarah Raven, Frampton Gwynette, Craig A. Stuck, Mark E. Geesey, Catherine Bradley, Jennifer L. Donovan, Alicia G. Hall, Shelley T. Sherk, Nancy R. Po Tags: SI on Neurodevelopmental Disorders Source Type: research